ArticleThe Journal of clinical investigation2014
Cryptococcosis: a model for the understanding of infectious diseases.
Article in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Deubiquitinase Ubp5 is essential for pulmonary immune evasion and hematogenous dissemination ofMycology · 2025Article
- Pleiotropic roles of LAMMER kinase, Lkh1 in stress responses and virulence ofFrontiers in cellular and infection microbiology · 2024Article
- The Cryptococcus gattii species complex: Unique pathogenic yeasts with understudied virulence mechanisms.PLoS neglected tropical diseases · 2022Review
- Article
- Simplified All-In-One CRISPR-Cas9 Construction for Efficient Genome Editing inJournal of fungi (Basel, Switzerland) · 2021Article
- Integrative Proteome and Acetylome Analyses of Murine Responses toFrontiers in microbiology · 2020Article
- Comparison of Clinical Features and Prognostic Factors of Cryptococcal Meningitis Caused by Cryptococcus neoformans in Patients With and Without Pulmonary Nodules.Mycopathologia · 2019Article
- Antimicrobial Octapeptin C4 Analogues Active against Cryptococcus Species.Antimicrobial agents and chemotherapy · 2018Article
- Convergent microevolution of Cryptococcus neoformans hypervirulence in the laboratory and the clinic.Scientific reports · 2017Article
- RNA Interference Screening Reveals Host CaMK4 as a Regulator of Cryptococcal Uptake and Pathogenesis.Infection and immunity · 2017Article
- Sirtuins in the phylum Basidiomycota: A role in virulence in Cryptococcus neoformans.Scientific reports · 2017Article
- GMP Synthase Is Required for Virulence Factor Production and Infection byThe Journal of biological chemistry · 2017Article
- Chemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformans.PloS one · 2016Article
- Article
- Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
The increase in immunosuppressed patient populations has correlated with a rise in clinical fungal infections, including cryptococcosis. Patient outcome following Cryptococcus infection is linked to initial fungal burden in cerebrospinal fluid (CSF) and fungal clearance following treatment; however, the role of the pathogen in disease prognosis is poorly defined. In this issue of the JCI, Sabiiti and colleagues have directly correlated phenotypic traits of Cryptococcus neoformans with clinical outcome of infected patients. A better understanding of both the host and pathogen contributions to disease etiology will provide more options for targeted treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.